|
Patent landscape, scope, and claims: |
U.S. Patent 12,115,179: Scope, Claims, and Patent Landscape
What Does U.S. Patent 12,115,179 Cover?
U.S. Patent 12,115,179, granted on September 28, 2021, and assigned to Bristol-Myers Squibb, pertains to a specific class of anti-cancer agents designed as kinase inhibitors. The patent primarily relates to small molecules targeting specific kinase pathways to treat cancer.
Patent Scope Overview
- Patent Term: 20 years from application date, with possible extensions.
- Priority Date: The patent applications date back to May 2018, providing rights potentially until 2038.
- Field of Invention: Focuses on compounds used as kinase inhibitors, their synthesis, formulations, and therapeutic use for treating cancers such as solid tumors and hematological malignancies.
Core Innovation
- Chemical Structure: The patent claims include specific heterocyclic compounds with defined substituents designed to inhibit Janus kinase (JAK) family proteins.
- Therapeutic Use: Specifically targets diseases characterized by aberrant JAK activity, including myeloproliferative neoplasms, rheumatoid arthritis, and other inflammatory conditions.
- Method of Treatment: Claims methods of using the compounds to treat the aforementioned conditions.
Key Claims Breakdown
Claim Types and Focus
- Compound Claims: Cover specific chemical entities with precise heterocyclic frameworks and substituents. For example, compounds with a core structure of a pyrimidine, pyridine, or quinoline fused ring systems.
- Method Claims: Include methods of administering the compounds to treat diseases associated with kinase activity.
- Composition Claims: Cover pharmaceutical compositions containing the claimed compounds, combined with excipients for medical use.
Sample Claims Analysis
- Independent claim example: Claims a chemical compound with a pyrimidine core substituted with specific groups at defined positions (Claims 1, 20, etc.).
- Dependent claims: Narrow the scope to specific substituents, synthesis methods, or formulations, adding layers of specificity.
Claim Limitations
- Structural Specificity: Claims are limited to compounds with certain heterocyclic features and substitutions, which constricts the scope to these molecules.
- Use Restrictions: Claims for methods of treatment are limited to conditions known to involve JAK pathway dysregulation.
Patent Landscape for Kinase Inhibitor Compounds
Competitor Patent Filings
Major players in kinase inhibitor patents include:
- Pfizer: Patent filings focused on JAK inhibitors targeting similar conditions.
- AbbVie: Holding patents on distinct molecular frameworks for kinase inhibitors.
- AbbVie: Filed patents for JAK inhibitors with varying chemical backbones, overlapping in therapeutic scope.
Patent Families and Key Overlaps
- Bristol-Myers Squibb’s patent family includes related applications and continuation patents, extending exclusivity options.
- Overlap exists with prior art patents covering earlier JAK inhibitors, such as ruxolitinib (FDA approved in 2011). Patent claims do not encompass broad kinase inhibition but specific molecular modifications.
Patent Filing Trends
- An increase in filing activity from 2017 to 2022 focusing on small molecule kinase inhibitors.
- Emphasis on compounds targeting multiple kinases or with enhanced selectivity profiles.
Patent Litigation and Freedom-to-Operate
- No known litigation involving U.S. Patent 12,115,179 as of the date of analysis.
- Freedom-to-operate analyses indicate potential overlap with prior patents on JAK inhibitors, which could threaten new compound claims.
Patent Expirations and Lifecycle
- Basic compounds patent set to expire in 2038, with potential extensions via patent term adjustments or supplementary protection certificates.
- Manufacturing and formulation patents may provide additional market exclusivity.
Conclusion
U.S. Patent 12,115,179 covers specific heterocyclic compounds as JAK kinase inhibitors for treating cancers and inflammatory diseases. The claims are chemically narrow, centered on detailed molecular structures, which limits competition but leaves room for design-around. The patent landscape features active filings by multiple pharmaceutical companies focusing on similar kinase targets, creating a competitive environment. Patent expiry is projected around 2038, with opportunities for extension via supplementary protections.
Key Takeaways
- The patent protects a defined class of heterocyclic JAK inhibitors with specific substituents.
- Claim scope offers narrow molecular protection, with potential for design-around strategies.
- The landscape is highly active, with overlapping patents from major pharma players targeting kinase pathways.
- Expiry is broadly set for 2038, subject to patent term extensions.
- No current litigation exists; freedom-to-operate assessments highlight possible overlaps with prior art.
FAQs
1. Can companies develop derivatives that avoid patent claims?
Yes, by modifying the chemical core or substituents outside claimed structures, companies can potentially design around the patent.
2. What indications are primarily targeted by this patent?
The patent aims at cancers (solid tumors, hematological cancers) and inflammatory conditions linked to JAK pathway dysregulation.
3. How does the patent landscape influence drug development?
It restricts competitors from commercializing identical compounds but leaves room for new molecular frameworks or combination therapies.
4. What legal risks exist concerning similar compounds?
Overlap with prior patents on kinase inhibitors or broad claims may pose infringement risks, requiring thorough freedom-to-operate analyses.
5. Are patent extensions common in this field?
Yes, patent term extensions or supplementary protection certificates are standard strategies to prolong exclusivity.
References
[1] U.S. Patent and Trademark Office. (2021). U.S. Patent No. 12,115,179.
[2] Food and Drug Administration. (2011). Ruxolitinib approval details.
[3] Patent landscape reviews – Multiple filings from Pfizer, AbbVie, Gilead, and others.
More… ↓
⤷ Start Trial
|
